Bayer Learning Session

Cancer recurrence can be a significant concern for prostate cancer survivors and their caregivers. In collaboration with Bayer Pharmaceutical, PHEN hosted a clinical trial learning session on this topic, an educational event to teach patients about the principles, processes, and practices involved in conducting and participating in clinical trials.

The focus of this learning session was the ARASTEP clinical trial, a trial aimed at determining if the combination of Darolutamide and ADT prolongs the time that patients with a prostate cancer biochemical recurrence live without their cancer getting worse (progressing).

Dr. Keith Crawford, PHEN's Director of Clinical Trials and Patient Education, is joined by Dr. Emmanuel S. Antonarakis, Professor of Medicine from the University of Minnesota, in a fireside chat discussion about the ARASTEP study and how patients can participate.

Prostate cancer patients with a rising PSA should view this recorded learning session to learn about the potential benefits of participating in the ARASTEP clinical trial.

Watch Online

Pfizer Learning Session

Clinical trials are an essential way for patients with advanced prostate cancer to get treatment. In collaboration with Pfizer Pharmaceuticals, PHEN hosted a clinical trial learning session on this topic. This learning session highlighted three coordinated Phase 3 trials that test a twice-daily oral pill (EZH2 inhibitor) added to today’s standard of care for men with metastatic castration‑resistant prostate cancer.

Neal Shore, MD

Medical Director

Carolina Urologic Research Center

These trials aimed to determine if combining the EZH2 inhibitor with treatments such as enzalutamide could delay resistance and prolong the time before the cancer worsens. The trials are randomized. Every participant continues to receive complete standard treatment.

Dr. Keith Crawford, PHEN’s Director of Clinical Trials and Patient Education, spoke with Dr. Neal Shore, Medical Director of the Carolina Urological Research Center. They discussed who may qualify, how often visits occur, common side effects, and why diverse participation is important.

Men with metastatic prostate cancer and their caregivers should view this session. They can learn how these clinical trials work, what to expect, and how to check eligibility with their care team.

Watch Online

MEVPRO-1

The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide or docetaxel).

View Patient Summary

MEVPRO-2

The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration–resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.

Visit Patient Summary

Highlighted Clinical Trials

Omaha - 003

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.

Omaha - 004

This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA).

MK-5684-01A

This clinical trial aims to test the safety and effectiveness of an investigational drug called MK-5684 to see if it may help stop or slow the spread of prostate cancer, specifically mCRPC.

View Patient Summary

For more clinical trials and information

Visit PHENTrials.com

Bayer Learning Session

Pfizer Learning Session

Highlighted Clinical Trials

Sponsored by